Cumulative response rates with dasatinib treatment according to BCR-ABL mutation status
| . | n . | n (%) or n/N (%) . | |||
|---|---|---|---|---|---|
| CHR . | MCyR . | CCyR . | MMR* . | ||
| All eligible patients | 1043 | 955 (92) | 639 (61) | 533 (51) | 399/992 (40) |
| Any BCR-ABL mutation | 402 | 362 (90) | 225 (56) | 175 (44) | 125/383 (33) |
| No BCR-ABL mutation | 641 | 593 (93) | 414 (65) | 358 (56) | 274/609 (45) |
| Patients with resistance or suboptimal response to imatinib | 805 | 735 (91) | 454 (56) | 360 (45) | 260/771 (34) |
| Any BCR-ABL mutation | 384 | 345 (90) | 211 (55) | 164 (43) | 115/367 (31) |
| No BCR-ABL mutation | 421 | 390 (93) | 243 (58) | 196 (47) | 145/404 (36) |
| Patients with intolerance to imatinib | 238 | 220 (92) | 185 (78) | 173 (73) | 139/221 (63) |
| Any BCR-ABL mutation | 18 | 17 (94) | 14 (78) | 11 (61) | 10/16 (63) |
| No BCR-ABL mutation | 220 | 203 (92) | 171 (78) | 162 (74) | 129/205 (63) |
| Patients with any BCR-ABL mutation | |||||
| Grouping by dasatinib IC50 | |||||
| IC50 greater than 3nM (excluding T315I)† | 121 | 110 (91) | 56 (46) | 39 (32) | 26/114 (23) |
| IC50 3nM or less‡ | 176 | 167 (95) | 107 (61) | 93 (53) | 65/171 (38) |
| IC50 unknown§ | 84 | 79 (94) | 60 (71) | 43 (51) | 34/78 (44) |
| Grouping by dose schedule | |||||
| 100 mg QD | 49 | 44 (90) | 27 (55) | 20 (41) | 17/47 (36) |
| 70 mg BID | 240 | 219 (91) | 140 (58) | 115 (48) | 79/231 (34) |
| 140 mg QD | 50 | 42 (84) | 28 (56) | 17 (34) | 11/46 (24) |
| 50 mg BID | 63 | 57 (90) | 30 (48) | 23 (37) | 18/59 (31) |
| Patients with 2 or more concurrent BCR-ABL mutations at baseline | 64 | 58 (91) | 33 (52) | 23 (36) | 16/61 (26) |
| 2 mutations | 50 | 47 (94) | 29 (58) | 21 (42) | 15/48 (31) |
| 3 mutations | 14 | 11 (79) | 4 (29) | 2 (14) | 1/13 (8) |
| . | n . | n (%) or n/N (%) . | |||
|---|---|---|---|---|---|
| CHR . | MCyR . | CCyR . | MMR* . | ||
| All eligible patients | 1043 | 955 (92) | 639 (61) | 533 (51) | 399/992 (40) |
| Any BCR-ABL mutation | 402 | 362 (90) | 225 (56) | 175 (44) | 125/383 (33) |
| No BCR-ABL mutation | 641 | 593 (93) | 414 (65) | 358 (56) | 274/609 (45) |
| Patients with resistance or suboptimal response to imatinib | 805 | 735 (91) | 454 (56) | 360 (45) | 260/771 (34) |
| Any BCR-ABL mutation | 384 | 345 (90) | 211 (55) | 164 (43) | 115/367 (31) |
| No BCR-ABL mutation | 421 | 390 (93) | 243 (58) | 196 (47) | 145/404 (36) |
| Patients with intolerance to imatinib | 238 | 220 (92) | 185 (78) | 173 (73) | 139/221 (63) |
| Any BCR-ABL mutation | 18 | 17 (94) | 14 (78) | 11 (61) | 10/16 (63) |
| No BCR-ABL mutation | 220 | 203 (92) | 171 (78) | 162 (74) | 129/205 (63) |
| Patients with any BCR-ABL mutation | |||||
| Grouping by dasatinib IC50 | |||||
| IC50 greater than 3nM (excluding T315I)† | 121 | 110 (91) | 56 (46) | 39 (32) | 26/114 (23) |
| IC50 3nM or less‡ | 176 | 167 (95) | 107 (61) | 93 (53) | 65/171 (38) |
| IC50 unknown§ | 84 | 79 (94) | 60 (71) | 43 (51) | 34/78 (44) |
| Grouping by dose schedule | |||||
| 100 mg QD | 49 | 44 (90) | 27 (55) | 20 (41) | 17/47 (36) |
| 70 mg BID | 240 | 219 (91) | 140 (58) | 115 (48) | 79/231 (34) |
| 140 mg QD | 50 | 42 (84) | 28 (56) | 17 (34) | 11/46 (24) |
| 50 mg BID | 63 | 57 (90) | 30 (48) | 23 (37) | 18/59 (31) |
| Patients with 2 or more concurrent BCR-ABL mutations at baseline | 64 | 58 (91) | 33 (52) | 23 (36) | 16/61 (26) |
| 2 mutations | 50 | 47 (94) | 29 (58) | 21 (42) | 15/48 (31) |
| 3 mutations | 14 | 11 (79) | 4 (29) | 2 (14) | 1/13 (8) |
CHR indicates complete hematologic response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response; IC50, median inhibition concentration; QD, once daily; and BID, twice daily.
MMR rates are calculated in patients who had BCR-ABL transcript levels assessed.
L248V, G250E, Q252H, E255K/V, V299L, F317L, L384M, and F486S.
M244V, Y253F/H, D276G, E279K, F311L, M351T, F359V, V379I, L387M, and H396P/R. Patients were excluded if they had a concurrent mutation with a dasatinib IC50 higher than 3 nM.
Patients were excluded if they had concurrent mutations with a known dasatinib IC50 (as listed in † and ‡).